...
首页> 外文期刊>Renal failure. >Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
【24h】

Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.

机译:小剂量骨化三醇对中度继发性甲状旁腺功能亢进症血液透析患者的长期影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Prevention of secondary hyperparathyroidism (SHPTH) and treatment of the moderate cases by small p.os doses of Vitamin D has not been thoroughly investigated on the long term, while large doses of Vitamin D have been successful in the short term treatment of this entity. We administered calcitriol p.os 0.5-1.0 microgram, according to iPTH levels, after each dialysis session, in 19 patients (group A) for 36 months. They were ten men and nine women, 63 years old (43-81), with iPTH levels > 4N (419 +/- 185 pg/mL). Seven adenomas were found in five of them (group A1). Serum Ca, phosphate (P) and alkaline phosphatase (AP) were measured every 15-30 days. Serum iPTH and aluminum as well as echogram or scanning of the parathyroid glands were checked every 6 months. Ten additional dialysis patients, seven men and three women, 54.5 years old (36-68), non-significantly different to group A in iPTH levels (290 +/- 225 pg/mL) with three adenomas in two of them (group B1) received no calcitriol and served as controls (group B). Calcitriol treatment significantly lowered serum iPTH levels in group A patients (from 419 +/- 185 to 173 +/- 142 pg/mL, p < 0.0001, delta iPTH: -246 +/- 161 pg/mL); iPTH remained stable in group B patients (delta iPTH: +7.9 +/- 116 pg/mL) with an intergroup significant difference at P < 0.0001. All other parameters measured did not show any significant change. No significant correlation of iPTH to Ca, P or AP was found in A. Initial iPTH levels were higher in A1 and B1 patients and decreased by calcitriol in A1 group. Adenomas in A1 patients did not change in number and size in contrast to B1 where new adenomas appeared (5 patients, 10 glands). Small doses of vitamin D lower high iPTH levels and prevent parathyroid gland hyperplasia. Existing hypertrophy is stabilized under calcitriol treatment both morphologically and biologically.
机译:长期以来,尚未对口服小剂量口服维生素D预防继发性甲状旁腺功能亢进症(SHPTH)和中度病例的治疗进行彻底研究,而大剂量服用维生素D已在短期内对该实体进行了成功治疗。每次透析后,我们根据iPTH水平在0.5到1.0微克之间给予骨化三醇,剂量为19个月(A组),持续36个月。他们是十名男性和九名女性,年龄在63岁(43-81),iPTH水平> 4N(419 +/- 185 pg / mL)。其中五个(A1组)中发现七个腺瘤。每15至30天测量一次血清Ca,磷酸盐(P)和碱性磷酸酶(AP)。每6个月检查一次血清iPTH和铝,以及超声图或甲状旁腺扫描。另有10名透析患者,分别为74.5岁(36-68岁)的7名男性和3名女性,其iPTH水平(290 +/- 225 pg / mL)与A组无显着差异,其中两个患有腺瘤(B1组) )未接受骨化三醇,并作为对照组(B组)。骨化三醇治疗显着降低了A组患者的血清iPTH水平(从419 +/- 185降至173 +/- 142 pg / mL,p <0.0001,δiPTH:-246 +/- 161 pg / mL); B组患者的iPTH保持稳定(δiPTH:+7.9 +/- 116 pg / mL),组间显着性差异为P <0.0001。测得的所有其他参数均未显示任何明显变化。在A中没有发现iPTH与Ca,P或AP的显着相关性。A1和B1患者的初始iPTH水平较高,而钙三醇在A1组降低了初始水平。与出现新腺瘤的B1相比,A1患者的腺瘤的数量和大小没有变化(5例,10个腺体)。小剂量的维生素D会降低iPTH的高水平,并防止甲状旁腺增生。在钙三醇处理下,无论从形态上还是生物学上,现有的肥大都得以稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号